NGS lung cancer panel was negative for mutations in ALK, ATK1, BRAF, CDK4, CTNNB1, DDR2, EGFR, FGFR2, FGFR3, HER2, HER3, HER4, JAK2, JAK3, KRAS, MAP2K1, MET, NRAS, PIK3CA, ROS1, and rearrangements in ALK, BRAF, FGFR3, NTRK, RET, and ROS1. This evidence concerns the gene ALK and lung carcinoma.